Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STUPITA01 subcutaneous versus intravenous piperacillin/tazobactam pharmacokinetic trial
2024-519663-17-01Phase 2Authorised
- Sponsor
- Azienda sanitaria universitaria Friuli Centrale
- Start
- Jun 2026
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of piperacillin and tazobactam in bacterial disease, pneumonia and febrile neutropenia (FN) (2 arms), sponsored by Azienda sanitaria universitaria Friuli Centrale. Planned start Jun 2026; status: authorised.
02
Drugs
piperacillintazobactam
03
Conditions
bacterial diseasepneumoniafebrile neutropenia (FN)
Beyond the preview
Go deeper on 2024-519663-17-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519663-17-01.